Galmed Pharmaceuticals Ltd.

Equities

GLMD

IL0011313900

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 02:48:40 2024-05-17 pm EDT			5-day change	1st Jan Change
0.3905 ^USD	-2.13%		-1.96%	-14.18%

Apr. 04	Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 15	Galmed Pharmaceuticals Ltd. Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of Nash and Liver Fibrosis	CI

Galmed Pharmaceuticals Announces Retirement of Maya Halpern as Chief Medical Officer and from its Board of Directors Effective as of April 9, 2016

February 11, 2016 at 08:00 am EST

Galmed Pharmaceuticals Ltd. announced that its Chief Medical Officer, Dr. Maya Halpern, has notified the Company that she will retiring from Galmed as Chief Medical Officer and from its Board of Directors effective as of April 9, 2016 due to her reaching retirement age.

Latest news about Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 04	CI
Galmed Pharmaceuticals Ltd. Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of Nash and Liver Fibrosis	Mar. 15	CI
Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 22	CI
Sector Update: Health Care Stocks Higher Late Tuesday Afternoon	Nov. 21	MT
Sector Update: Health Care	Nov. 21	MT
Top Midday Decliners	Nov. 21	MT
Galmed Pharmaceuticals Expects Minimum Six Months Delay in Primary Sclerosing Cholangitis Study	Nov. 20	MT
Galmed Pharmaceuticals Ltd. Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis	23-09-26	CI
Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Maxim Upgrades Galmed Pharmaceuticals to Buy From Hold, Price Target is $4	23-07-24	MT
Top Midday Decliners	23-07-14	MT
Galmed Pharmaceuticals Prices $7 Million Securities Offering; Shares Slump	23-07-14	MT
Top Premarket Decliners	23-07-13	MT
Galmed Pharmaceuticals Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-06-01	CI
Galmed Pharmaceuticals Ltd. Announces Initiation of a Clinical Development Program to Evaluate Aramchol meglumine for the Treatment of Primary Sclerosing Cholangitis	23-05-09	CI
Wall Street Set to Open Higher; April Jobs Report Tops Expectations	23-05-05	MT
Top Premarket Gainers	23-05-05	MT
Galmed Pharmaceuticals Forms a Strategic Partnership with OnKai	23-05-04	CI
Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-29	CI
Galmed Pharmaceuticals Receives US Patent for Aramchol Meglumine Salt	23-02-08	MT
Galmed Pharmaceuticals Ltd. Announces Issuance of New Composition of Matter Patent for Aramchol Meglumine Salt	23-02-08	CI
OnKai Inc. announced that it expects to receive $2.5 million in funding from Galmed Pharmaceuticals Ltd. and other investors	23-01-04	CI
Galmed Pharmaceuticals Says Open-label Part of Phase 3 Aramchol Shows Fibrosis Improvement in Nonalcoholic Steatohepatitis Patients	23-01-04	MT
Galmed Pharmaceuticals Ltd. Reports Results from the Open-Label Part of the Armor Study Showing Improvements in Histology, Imaging, and Biomarkers with Aramchol	23-01-04	CI
Galmed Pharmaceuticals Gets Extension to Regain Compliance With Nasdaq's Bid Price Requirement	22-12-15	MT

Chart Galmed Pharmaceuticals Ltd.

Duration

Period

More charts

Company Profile

Galmed Pharmaceuticals is a Israeli-based clinical-stage biopharmaceutical company.The activiti of the Company is focused on the development therapy for treating liver diseases. Arachmol, the main product of Galmed Pharmaceuticals, is a liver-targeted stearoyl-coenzyme A desaturase1 used in oral therapy for the treatment of NASH (Non-alcoholic Steatohepatitis).

Sector

Biotechnology & Medical Research

Calendar

2025-05-06 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.399 USD

Average target price

1 USD

Spread / Average Target

+150.63%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
GALMED PHARMACEUTICALS LTD.	-14.18%	2.4M
VERTEX PHARMACEUTICALS INCORPORATED	+9.41%	114B
REGENERON PHARMACEUTICALS, INC.	+11.37%	104B
BIONTECH SE	-13.80%	22.41B
ARGENX SE	-1.05%	22.28B
GENMAB A/S	-5.29%	19.07B
WUXI APPTEC CO., LTD.	-38.29%	18B
BEIGENE, LTD.	-4.14%	17.89B
NEUROCRINE BIOSCIENCES, INC.	+7.64%	14.28B
SAREPTA THERAPEUTICS, INC.	+34.53%	12.55B

Bio Therapeutic Drugs